Patents by Inventor Iisa Höglund

Iisa Höglund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Androgen receptor modulating compounds
    Patent number: 11046713
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: June 29, 2021
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • ANDROGEN RECEPTOR MODULATING COMPOUNDS
    Publication number: 20200299307
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 24, 2020
    Publication date: September 24, 2020
    Inventors: Gerd WOHLFAHRT, Olli TÖRMÄKANGAS, Harri SALO, Iisa HÖGLUND, Arja KARJALAINEN, Pia KOIVIKKO, Patrik HOLM, Sirpa RASKU, Anniina VESALAINEN
  • Androgen receptor modulating compounds
    Patent number: 10711013
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: July 14, 2020
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • ANDROGEN RECEPTOR MODULATING COMPOUNDS
    Publication number: 20190100536
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 25, 2018
    Publication date: April 4, 2019
    Inventors: Gerd WOHLFAHRT, Olli TÖRMÄKANGAS, Harri SALO, Iisa HÖGLUND, Arja KARJALAINEN, Pia KOIVIKKO, Patrik HOLM, Sirpa RASKU, Anniina VESALAINEN
  • Androgen receptor modulating compounds
    Patent number: 10118933
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: November 6, 2018
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • Androgen receptor modulating compounds
    Patent number: 9657003
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 23, 2017
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES
    Publication number: 20170137387
    Abstract: Compounds of formula (I), wherein R1 through R8 are as defined in the claims, exhibit a positive allosteric GABAB modulator effect and are thus useful as positive allosteric modulators of the GABAB receptor.
    Type: Application
    Filed: May 8, 2015
    Publication date: May 18, 2017
    Inventors: Peteris PRUSIS, Iisa HÖGLUND, Olli TÖRMAKANGAS, Ari HIETANEN, Riina ARVELA, Anniina VESALAINEN, Terhi HEIKKINEN
  • ANDROGEN RECEPTOR MODULATING COMPOUNDS
    Publication number: 20150203479
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 23, 2015
    Inventors: Gerd WOHLFAHRT, Olli TÖRMÄKANGAS, Harri SALO, Iisa HÖGLUND, Arja KARJALAINEN, Pia KNUUTTILA, Patrik HOLM, Sirpa RASKU, Anniina VESALAINEN
  • Androgen receptor modulating compounds
    Patent number: 8975254
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: March 10, 2015
    Assignee: Orion Corporation
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Knuuttila, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4
    Publication number: 20100048549
    Abstract: The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst1 and/or sst4 and can be used for the treatment or diagnosis of diseases or conditions wherein sst1 and/or sst4 agonists or antagonists are indicated to be useful.
    Type: Application
    Filed: May 16, 2006
    Publication date: February 25, 2010
    Inventors: Jussi Tomperi, Harri Salo, Oili Kallatsa, Pia Knuuttila, Päivi Laakso, Iisa Höglund, Anna-Marja Hoffrén, Kurt Kokko, Pauli Saarenketo, Mia Engström, Siegfried Wurster
  • Dervatives of quinoline as alpha-2 antagonists
    Patent number: 6593324
    Abstract: A compound of formula I, wherein A, Ra, Rb, R1 to R5, m and t are as defined as disclosed, or a pharmaceutically acceptable salt or ester thereof, useful as an alpha-2 antagonist. The compounds I can be used for the treatment of diseases or conditions where alpha-2 antagonists are indicated to be effective.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: July 15, 2003
    Assignees: Orion Corporation, Oy Juvantia Pharma Ltd.
    Inventors: Siegfried Wurster, Mia Engström, Juha-Matti Savola, Iisa Höglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffrén, Harri Elias Salo